ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
External link for ArriVent Biopharma
Join @ArriVent BioPharma (#AVBP) for a virtual KOL event on Monday, Sep. 9 at 4:30 pm ET featuring Xiuning Le, MD, PhD (The University of Texas MD Anderson Cancer Center) to discuss the unmet need and current treatment landscape for non-small cell lung cancer (NSCLC) EGFR PACC mutations. Register here: https://lnkd.in/gB4rUZXB
This content isn’t available here
Access this content and more in the LinkedIn app